Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Ionis Pharmaceuticals, Inc. (IONS) had Cost of Goods Sold of $15.91M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$943.71M |
|
$-381.39M |
|
|
Cost of Goods Sold |
$15.91M |
$927.80M |
|
$1.33B |
|
$-381.68M |
|
$2.08M |
|
$-379.60M |
|
$-389.82M |
|
$-381.39M |
|
$-381.39M |
|
$-381.39M |
|
$-391.56M |
|
$-381.68M |
|
$-375.82M |
|
160.01M |
|
160.01M |
|
$-2.38 |
|
$-2.38 |
|
| Balance Sheet Financials | |
$2.99B |
|
$123.05M |
|
$533.20M |
|
$3.52B |
|
$781.57M |
|
$1.35B |
|
$2.25B |
|
$3.03B |
|
$489.09M |
|
$489.09M |
|
$489.09M |
|
163.31M |
|
| Cash Flow Statement Financials | |
$-268.58M |
|
$-277.78M |
|
$675.84M |
|
$242.08M |
|
$372.26M |
|
$130.18M |
|
$133.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.83 |
|
-- |
|
-- |
|
0.73 |
|
3.64 |
|
98.31% |
|
-40.45% |
|
-40.45% |
|
-39.82% |
|
-40.22% |
|
-40.41% |
|
$-320.03M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
1.58 |
|
14.29 |
|
25.55 |
|
-77.98% |
|
-77.98% |
|
-10.82% |
|
-20.77% |
|
$2.99 |
|
$-2.00 |
|
$-1.68 |
|